Logo image of RCKT

ROCKET PHARMACEUTICALS INC (RCKT) Stock Fundamental Analysis

NASDAQ:RCKT - Nasdaq - US77313F1066 - Common Stock - Currency: USD

2.745  -0.08 (-3%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to RCKT. RCKT was compared to 557 industry peers in the Biotechnology industry. RCKT may be in some trouble as it scores bad on both profitability and health. RCKT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RCKT has reported negative net income.
RCKT had a negative operating cash flow in the past year.
RCKT had negative earnings in each of the past 5 years.
RCKT had a negative operating cash flow in each of the past 5 years.
RCKT Yearly Net Income VS EBIT VS OCF VS FCFRCKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

RCKT has a Return On Assets (-54.77%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -62.61%, RCKT is in line with its industry, outperforming 59.25% of the companies in the same industry.
Industry RankSector Rank
ROA -54.77%
ROE -62.61%
ROIC N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
RCKT Yearly ROA, ROE, ROICRCKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCKT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCKT Yearly Profit, Operating, Gross MarginsRCKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for RCKT has been increased compared to 1 year ago.
RCKT has more shares outstanding than it did 5 years ago.
RCKT has a worse debt/assets ratio than last year.
RCKT Yearly Shares OutstandingRCKT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RCKT Yearly Total Debt VS Total AssetsRCKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

RCKT has an Altman-Z score of -1.85. This is a bad value and indicates that RCKT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RCKT (-1.85) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.05 indicates that RCKT is not too dependend on debt financing.
The Debt to Equity ratio of RCKT (0.05) is worse than 62.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -1.85
ROIC/WACCN/A
WACCN/A
RCKT Yearly LT Debt VS Equity VS FCFRCKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 9.19 indicates that RCKT has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.19, RCKT is doing good in the industry, outperforming 74.87% of the companies in the same industry.
RCKT has a Quick Ratio of 9.19. This indicates that RCKT is financially healthy and has no problem in meeting its short term obligations.
RCKT has a Quick ratio of 9.19. This is in the better half of the industry: RCKT outperforms 75.04% of its industry peers.
Industry RankSector Rank
Current Ratio 9.19
Quick Ratio 9.19
RCKT Yearly Current Assets VS Current LiabilitesRCKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

RCKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.36%, which is quite good.
EPS 1Y (TTM)8.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RCKT will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.44% on average per year.
Based on estimates for the next years, RCKT will show a very strong growth in Revenue. The Revenue will grow by 523.09% on average per year.
EPS Next Y12.95%
EPS Next 2Y14.32%
EPS Next 3Y24%
EPS Next 5Y13.44%
Revenue Next Year46213%
Revenue Next 2Y5723.39%
Revenue Next 3Y1958.62%
Revenue Next 5Y523.09%

3.3 Evolution

RCKT Yearly Revenue VS EstimatesRCKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
RCKT Yearly EPS VS EstimatesRCKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RCKT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RCKT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCKT Price Earnings VS Forward Price EarningsRCKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCKT Per share dataRCKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as RCKT's earnings are expected to grow with 24.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.32%
EPS Next 3Y24%

More info and screens

0

5. Dividend

5.1 Amount

RCKT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (6/20/2025, 10:58:54 AM)

2.745

-0.08 (-3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners90.7%
Inst Owner Change-0.82%
Ins Owners2.6%
Ins Owner Change20.28%
Market Cap295.75M
Analysts78.33
Price Target15.61 (468.67%)
Short Float %12.21%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.95%
Min EPS beat(2)10.56%
Max EPS beat(2)15.34%
EPS beat(4)3
Avg EPS beat(4)8.29%
Min EPS beat(4)-1.16%
Max EPS beat(4)15.34%
EPS beat(8)6
Avg EPS beat(8)8.19%
EPS beat(12)7
Avg EPS beat(12)3.49%
EPS beat(16)10
Avg EPS beat(16)3.12%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-60.02%
PT rev (3m)-60.55%
EPS NQ rev (1m)2.65%
EPS NQ rev (3m)9.18%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.7%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)50.42%
Revenue NY rev (1m)-59.85%
Revenue NY rev (3m)-73.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.85
EV/EBITDA N/A
EPS(TTM)-2.63
EYN/A
EPS(NY)-1.89
Fwd EYN/A
FCF(TTM)-1.98
FCFYN/A
OCF(TTM)-1.94
OCFYN/A
SpS0
BVpS3.83
TBVpS3.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.77%
ROE -62.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 41.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.19
Quick Ratio 9.19
Altman-Z -1.85
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)144.02%
Cap/Depr(5y)620.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.15%
EPS Next Y12.95%
EPS Next 2Y14.32%
EPS Next 3Y24%
EPS Next 5Y13.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year46213%
Revenue Next 2Y5723.39%
Revenue Next 3Y1958.62%
Revenue Next 5Y523.09%
EBIT growth 1Y-2.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.46%
EBIT Next 3Y35.5%
EBIT Next 5YN/A
FCF growth 1Y-3.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.2%
OCF growth 3YN/A
OCF growth 5YN/A